Treatment Update of Autoimmune Blistering Diseases.

Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors Antibodies, Monoclonal / therapeutic use Antibodies, Monoclonal, Humanized / therapeutic use Autoimmune Diseases / immunology Dermatitis Herpetiformis / immunology Epidermolysis Bullosa Acquisita / immunology Female Glucocorticoids / therapeutic use Humans Immunoglobulins, Intravenous / therapeutic use Immunologic Factors / therapeutic use Immunosuppressive Agents / therapeutic use Immunotherapy, Adoptive Pemphigoid Gestationis / immunology Pemphigoid, Benign Mucous Membrane / immunology Pemphigoid, Bullous / immunology Pemphigus / immunology Plasmapheresis Pregnancy Protein Kinase Inhibitors / therapeutic use Rituximab / therapeutic use Skin Diseases, Vesiculobullous / immunology p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors
Autoimmune blistering diseases Emerging Rituximab Treatment

Journal

Dermatologic clinics
ISSN: 1558-0520
Titre abrégé: Dermatol Clin
Pays: United States
ID NLM: 8300886

Informations de publication

Date de publication:
Apr 2019
Historique:
entrez: 10 3 2019
pubmed: 10 3 2019
medline: 2 7 2019
Statut: ppublish

Résumé

The treatment of refractory autoimmune blistering diseases (AIBDs) has always been a challenge. Because randomized controlled trials are lacking, treatment has been based on analysis of anecdotal data. The last 2 decades has seen the use of rituximab become a conventional treatment in the therapeutic armamentarium of AIBDs, leading to its Food and Drug Administration indication for pemphigus vulgaris in 2018. We review the current updated data on the use of rituximab including dosing, protocols, and its role in the algorithm of AIBDs. In addition, we discuss several promising novel emerging therapeutic agents for AIBDs.

Identifiants

DOI: 10.1016/j.det.2018.12.003 PMID: 30850044
pubmed: 30850044
pii: S0733-8635(18)31145-8
doi: 10.1016/j.det.2018.12.003
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Monoclonal, Humanized 0
Glucocorticoids 0
Immunoglobulins, Intravenous 0
Immunologic Factors 0
Immunosuppressive Agents 0
Protein Kinase Inhibitors 0
Rituximab 4F4X42SYQ6
ocrelizumab A10SJL62JY
veltuzumab BPD4DGQ314
Agammaglobulinaemia Tyrosine Kinase EC 2.7.10.2
BTK protein, human EC 2.7.10.2
p38 Mitogen-Activated Protein Kinases EC 2.7.11.24
ofatumumab M95KG522R0
obinutuzumab O43472U9X8

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

215-228

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Khalaf Kridin (K)

Department of Dermatology, Rambam Health Care Campus, POB 9602, Haifa 31096, Israel.

Christine Ahn (C)

Department of Dermatology, Wake Forest School of Medicine, Wake Forest University, 4618 Country Club Road, Winston-Salem, NC 27104, USA.

William C Huang (WC)

Department of Dermatology, Wake Forest School of Medicine, Wake Forest University, 4618 Country Club Road, Winston-Salem, NC 27104, USA.

Ahmed Ansari (A)

College of Medicine (Lake Nona), University of Central Florida, 6850 Lake Nona Boulevard, Orlando, FL 32827, USA.

Naveed Sami (N)

Department of Medicine, University of Central Florida, Health Sciences Campus at Lake Nona, 2627 Northampton Avenue, Orlando, FL 32827-7408, USA. Electronic address: naveed.sami@ucf.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-tyrosine kinases › Agammaglobulinaemia tyrosine kinase › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Dermatite herpétiforme › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Dermatoses vésiculobulleuses › Épidermolyse bulleuse › Épidermolyse bulleuse acquise › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Hormones › Glucocorticoïdes › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Immunoglobulines par voie veineuse › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunosuppresseurs › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Transfert adoptif › Immunothérapie adoptive › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Dermatoses vésiculobulleuses › Pemphigoïde gravidique › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Dermatoses vésiculobulleuses › Pemphigoïde bénigne des muqueuses › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Pemphigoïde bulleuse › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Pemphigus › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Procédures de chirurgie opératoire › Circulation extracorporelle › Plasmaphérèse › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Reproduction › Grossesse › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux d'origine murine › Rituximab › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Dermatoses vésiculobulleuses › Treatment Update of Autoimmune Blistering Diseases.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Mitogen-Activated Protein Kinases › p38 Mitogen-Activated Protein Kinases › Treatment Update of Autoimmune Blistering Diseases.